For instance, in metastatic melanoma, five-year survival rates have significantly improved due to therapies targeting PD-1, while in NSCLC, ICIs have shown survival benefits, even in advanced stages of the disease [4]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.